IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection

Table 2 Hepatitis B virus genotype and interferon-α treatment responses

HBV genotype	Total	Virological response1		HBeAg seroconversion2		Combined response3		Sustained response4
		R	%	R	%	R	%	R	%
Type A	8	3	37.5	1	12.5	1	12.5	1	12.5
Type B	94	42	44.7	38	40.4	19	20.2	37	39.4
Type C	15	10	66.7	5	33.3	5	33.3	6	40.0
Type B + C	80	22	27.5	11	13.8	7	8.8	10	12.5

¹Virological response was defined as serum HBV DNA level < 2000 IU/L at the end of the treatment;

²HBeAg seroconversion was defined as the loss of HBeAg and the presence of anti-HBe at the end of the treatment;

³Combined response was defined as the combination of HBeAg seroconversion and virological response, as well as the normalization of serum ALT at the end of the treatment;

⁴Sustained response was defined as the combined response at week 72 after the first dose of the treatment. HBV: Hepatitis B virus; R: Response; HBeAg: Hepatitis B e antigen.